Piamsomboon S, Termrungruanglert W, Kudelka A P, Edwards C L, Freedman R S, Mountain C F, Delclos L, Aapro M S, DeCaro L, Bianca J, Verschraegen C F, Kavanagh J J
Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Anticancer Drugs. 1996 Sep;7(7):800-4. doi: 10.1097/00001813-199609000-00014.
Recurrent and metastatic cervical carcinoma has very poor prognosis, mainly because there is no effective systemic therapy which would increase the duration of survival. Biologic agents have recently been found to have activity in cervical carcinoma. The combination of interferon (IFN)-alpha and 13-cis-retinoic acid had additive and synergistic antitumor activity. Both have antiviral, immunoregulatory and antiangiogenic properties, and are known to modulate malignant cell differentiation and proliferation. We report two patients with recurrent squamous cell carcinoma (SCC) of the cervix who had small-volume progressive metastatic disease, and were treated with a combination of IFN-alpha and 13-cis-retinoic acid. The first patient had pelvic lymph node metastases and the other had lung metastases. The previously progressive diseases remained stable for a prolonged period of time, 3 and 4 years, with a good quality of life. These cases suggest the possibility of using IFN-alpha and 13-cis-retinoic acid as a treatment for small-volume residual disease or as postinduction therapy in patients at high risk for disease recurrence.
复发性和转移性宫颈癌的预后非常差，主要是因为没有有效的全身治疗方法能够延长生存期。最近发现生物制剂在宫颈癌中具有活性。α-干扰素（IFN）和13-顺式维甲酸联合使用具有相加和协同的抗肿瘤活性。两者都具有抗病毒、免疫调节和抗血管生成特性，并且已知可调节恶性细胞的分化和增殖。我们报告了两名复发性宫颈鳞状细胞癌（SCC）患者，他们患有小体积进行性转移性疾病，并接受了α-干扰素和13-顺式维甲酸联合治疗。第一名患者有盆腔淋巴结转移，另一名有肺转移。先前进展的疾病在3年和4年的长时间内保持稳定，生活质量良好。这些病例提示了使用α-干扰素和13-顺式维甲酸治疗小体积残留疾病或作为疾病复发高危患者诱导后治疗的可能性。
